Holen Sie sich die Stockscreener-App
26.52
1.08%
-0.29
Handel nachbörslich:
26.52
Schlusskurs vom Vortag:
$26.81
Offen:
$26.86
24-Stunden-Volumen:
689.29K
Relative Volume:
1.17
Marktkapitalisierung:
$1.90B
Einnahmen:
$81.26M
Nettoeinkommen (Verlust:
$-102.66M
KGV:
-19.39
EPS:
-1.3678
Netto-Cashflow:
$-77.62M
1W Leistung:
-0.19%
1M Leistung:
-3.46%
6M Leistung:
+9.45%
1J Leistung:
+64.11%
1-Tages-Spanne:
$26.23
$26.88
1-Wochen-Bereich:
$26.14
$27.89
52-Wochen-Spanne:
$16.00
$31.34
Zymeworks Inc. Stock (ZYME) Company Profile
Firmenname
Zymeworks Inc.
Sektor
Branche
Telefon
604-678-1388
Adresse
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
26.52 | 1.90B | 81.26M | -102.66M | -77.62M | -1.3678 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-12-03 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-10-24 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2025-10-14 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | Eingeleitet | B. Riley Securities | Buy |
| 2025-05-20 | Eingeleitet | TD Cowen | Buy |
| 2024-12-16 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Fortgesetzt | Wells Fargo | Overweight |
| 2023-01-04 | Bestätigt | H.C. Wainwright | Neutral |
| 2022-12-20 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Fortgesetzt | Wells Fargo | Overweight |
| 2022-05-05 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-03-15 | Eingeleitet | Evercore ISI | Outperform |
| 2021-12-10 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Fortgesetzt | Guggenheim | Neutral |
| 2021-10-07 | Eingeleitet | Jefferies | Hold |
| 2021-03-31 | Eingeleitet | Credit Suisse | Outperform |
| 2021-02-25 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-01-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-06 | Eingeleitet | SVB Leerink | Outperform |
| 2020-01-10 | Eingeleitet | Wolfe Research | Outperform |
| 2019-12-09 | Eingeleitet | JP Morgan | Neutral |
| 2019-11-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-09-30 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Eingeleitet | Stifel | Buy |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-05-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Zymeworks Inc. Aktie (ZYME) Neueste Nachrichten
Theravance Biopharma Insider Brett Grimaud Reports Complete Share Cancellation Following Zymeworks Merger - Kalkine Media
Vancouver biotech Zymeworks closes US$929M Theravance deal - Business in Vancouver
Zymeworks Inc. (ZYME) Stock Price, News, Quote & History - Yahoo! Finance Canada
Zymeworks closes out acquisition of Theravance for USD 929m - AllSci
What Does the Theravance Acquisition Add for Zymeworks (NASDAQ:ZYME)? - Kalkine Media
Zymeworks Completes Acquisition of Theravance Biopharma - Indovizka.com
Zymeworks Finalizes Merger with Theravance Biopharma and Launches $350M Senior Secured Notes - Kalkine Media
Zymeworks completes acquisition of Theravance Biopharma By Investing.com - Investing.com Canada
Zymeworks completes acquisition of Theravance Biopharma - Investing.com
Zymeworks Raises $350 Million Notes and Launches Ampreloxetine CVR - TradingView
A $350 million debt issue helped fund Zymeworks (ZYME)'s Theravance acquisition, with cash due per eligible share. - Stock Titan
Squarepoint Ops LLC Reduces Holdings in Zymeworks Inc. $ZYME - MarketBeat
Zymeworks stock gains on fresh Wolfe Research coverage - AD HOC NEWS
Zymeworks stock gains on merger approval and a $41 target - AD HOC NEWS
Zymeworks Inc. (NASDAQ:ZYME) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Theravance Biopharma Shareholders Endorse Merger with Zymeworks Inc. - kalkinemedia.com
Zymeworks Stock Price Forecast. Should You Buy ZYME? - StockInvest.us
Theravance Biopharma shareholders approve merger with Zymeworks - Investing.com
Theravance Biopharma shareholders approve merger with Zymeworks By Investing.com - Investing.com UK
Zymeworks' Theravance Deal Is A Breath Of Fresh Cash Flow (NASDAQ:ZYME) - Seeking Alpha
Zymeworks stock gains as Theravance deal and valuation draw investor focus - AD HOC NEWS
Zymeworks Inc. (ZYME): Investor Outlook Reveals 50% Upside Potential In Biotech Arena - DirectorsTalk Interviews
Why Is Wolfe Research Starting Coverage On Zymeworks (NASDAQ:ZYME)? - Kalkine Media
Wolfe Research Begins Coverage on Zymeworks (NASDAQ:ZYME) - MarketBeat
Zymeworks Inc. at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 238,026 Shares of Zymeworks Inc. $ZYME - MarketBeat
Wellington Management Group LLP Takes $2.88 Million Position in Zymeworks Inc. $ZYME - MarketBeat
Legal & General Group Plc Makes New $1.13 Million Investment in Zymeworks Inc. $ZYME - MarketBeat
Bank of New York Mellon Corp Acquires New Holdings in Zymeworks Inc. $ZYME - MarketBeat
JPMorgan Chase & Co. Boosts Zymeworks (NASDAQ:ZYME) Price Target to $33.00 - MarketBeat
Zymeworks (ZYME) Falls 3.7% to $29.9 as Shares Slip Below $30RVOL Breakout - careplusvn.com
Zymeworks (NASDAQ:ZYME) Hits New 1-Year HighTime to Buy? - MarketBeat
Zymeworks stock hits 52-week high at 30.75 USD - Investing.com
Zymeworks stock hits 52-week high at 30.75 USD By Investing.com - Investing.com Nigeria
ZJM stock holds near its latest trade. Zymeworks data still drives the setup - AD HOC NEWS
Enterprise value to revenue forward of Zymeworks Inc. – NASDAQ:ZYME - TradingView
Man Group plc Invests $5.51 Million in Zymeworks Inc. $ZYME - marketbeat.com
4,251,030 Shares in Zymeworks Inc. $ZYME Bought by BlackRock Inc. - marketbeat.com
Zymeworks stock holds near $28.27 as market cap tops $2.01 billion - ad-hoc-news.de
FY2026 EPS Estimates for Zymeworks Raised by HC Wainwright - MarketBeat
Is Zymeworks (ZYME) Stock Fully Priced After Its 301% Run? - Yahoo Finance
Zymeworks shifts to revenue growth after FDA ap... - Pluang
HC Wainwright Has Strong Estimate for Zymeworks Q3 Earnings - marketbeat.com
Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval - Seeking Alpha
Zymeworks moves higher as Street cheers Ziihera regimen approval - Seeking Alpha
Jazz Pharmaceuticals Wins FDA Approval For Two Advanced Gastric Cancer Regimens - Sahm
Zymeworks stock hits 52-week high at 29.81 USD By Investing.com - Investing.com South Africa
Zymeworks stock rating reiterated at Market Outperform by Citizens - Investing.com India
Zymeworks Announces FDA Approval of Ziihera-Based Regimens for First-Line HER2-Positive Gastroesophageal Adenocarcinoma and $250 Million Milestone Payment from Jazz Pharmaceuticals - quiverquant.com
U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma - NTB Kommunikasjon
Zymeworks Shares Rise Ahead of Key FDA Decision on Zanidatamab - Yahoo Finance
Finanzdaten der Zymeworks Inc.-Aktie (ZYME)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):